Home » Healthcare » China Human Insulin Market

China Human Insulin Market

China Human Insulin Market By Device (Pens, Syringes, Others); By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes); By Insulin (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Others); By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
China Human Insulin Market Size 2023	USD 2,550.64 million
China Human Insulin Market, CGR	6.43%
China Human Insulin Market Size 2032	UUSD 4,472.55 million

Market Overview

China Human Insulin market size was valued at USD 2,550.64 million in 2023 and is anticipated to reach USD 4,472.55 million by 2032, at a CAGR of 6.43% during the forecast period (2023-2032).

The market for human insulin in China is driven by the increasing prevalence of diabetes, a rapidly aging population, and growing healthcare awareness. As the country continues to urbanize, lifestyle changes have led to a rise in the number of diabetes cases, creating a strong demand for insulin. Additionally, advancements in insulin delivery technologies and the expansion of healthcare infrastructure are fueling market growth. The Chinese government’s support through policies aimed at improving diabetes care, along with rising health insurance coverage, further contributes to market expansion. With a focus on improving accessibility and affordability, both local and international pharmaceutical companies are increasingly investing in China, driving competition and innovation. Moreover, the adoption of biosimilars and the shift towards personalized medicine are expected to significantly impact the market, offering new treatment options for diabetes patients. These trends position the Chinese human insulin market for continued growth and development.

Geographically, the human insulin market in China is driven by key regions such as Beijing, Shanghai, Guangzhou, and Shenzhen, each experiencing significant growth due to factors like urbanization, rising diabetes prevalence, and improvements in healthcare infrastructure. These cities are central to the demand for advanced insulin delivery technologies, including insulin pens, pumps, and biosimilars. Key players in the Chinese human insulin market include global pharmaceutical giants like Novo Nordisk, Eli Lilly, and Pfizer, alongside prominent local companies such as Tonghua Dongbao Pharmaceutical and Gan & Lee Pharmaceuticals. These companies are increasingly focusing on expanding their product portfolios and distribution networks in China to tap into the growing demand for insulin. With the continued adoption of innovative insulin management solutions and a government push for better diabetes care, these key players are poised to benefit from the expanding market.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The China human insulin market was valued at USD 2,550.64 million in 2023 and is expected to reach USD 4,472.55 million by 2032, growing at a CAGR of 6.43% during the forecast period (2023-2032).

The global human insulin market was valued at USD 21,000 million in 2023 and is projected to reach USD 31,208 million by 2032, growing at a CAGR of 4.50% from 2023 to 2032.
Rising diabetes prevalence, especially due to urbanization and changing lifestyles, is a primary driver of insulin demand.

Increasing healthcare awareness and government policies focused on diabetes management are propelling market growth.
The adoption of biosimilars and innovative insulin delivery technologies, such as insulin pens and pumps, is a key market trend.
Competitive players include Novo Nordisk, Eli Lilly, Pfizer, Gan & Lee Pharmaceuticals, and Tonghua Dongbao, intensifying market competition.
The market faces pricing pressures, regulatory challenges, and the need for cost-effective solutions.
Regions like Beijing, Shanghai, Guangzhou, and Shenzhen lead the market due to high urbanization, healthcare access, and rising diabetes cases.

Report Scope

This report segments the China Human Insulin Market as follows:

Market Drivers

Rising Prevalence of Diabetes

The increasing prevalence of diabetes in China is one of the primary drivers of the human insulin market. For instance, China has the highest number of diabetics globally, with approximately 141 million people affected by the condition in 2021. As urbanization accelerates and lifestyle changes, such as poor diet and reduced physical activity, become more common, the incidence of type 2 diabetes is rising at an alarming rate. This growing patient pool significantly boosts the demand for diabetes treatments, especially insulin. As the prevalence of diabetes continues to rise, the need for effective insulin therapies becomes even more critical, leading to sustained market growth.

Aging Population

China’s aging population is another key driver contributing to the growth of the human insulin market. For instance, the proportion of individuals aged 60 and above in China is steadily increasing, with demographic trends indicating a significant rise in elderly populations over the next decade. Older adults are more susceptible to developing chronic conditions like diabetes, which further exacerbates the demand for insulin. With many elderly individuals being diagnosed with both type 1 and type 2 diabetes, the market for human insulin is seeing a significant boost. The Chinese government’s recognition of this demographic shift has led to increased healthcare investments and policies aimed at improving the management of diabetes in elderly populations, thereby further driving market expansion.

Government Initiatives and Healthcare Improvements

Government initiatives and healthcare reforms play a crucial role in driving the growth of the human insulin market in China. The Chinese government has made significant strides in improving access to healthcare services, particularly for chronic conditions like diabetes. Policies that promote better diabetes management, subsidize insulin prices, and enhance healthcare infrastructure are directly supporting the insulin market. Additionally, the growing availability of health insurance coverage for diabetes treatment has made insulin more accessible to a larger portion of the population. With the government continuing to emphasize public health improvements, especially for individuals suffering from chronic diseases, the insulin market is poised for sustained growth.

Technological Advancements and Biosimilars

Technological advancements in insulin delivery systems and the rise of biosimilars are also playing a pivotal role in driving market growth. Innovations such as insulin pens, pumps, and continuous glucose monitoring devices are enhancing the patient experience by providing more efficient and less invasive methods of insulin administration. Additionally, the increasing availability of biosimilar insulin products is improving affordability and accessibility, particularly for patients who cannot afford branded insulin. As biosimilars enter the market, competition intensifies, leading to reduced prices and greater market penetration. The combination of these technological innovations and the growing adoption of biosimilars is expected to significantly impact the human insulin market in China, making diabetes management more effective and affordable for a broader segment of the population.

Market Trends

Technological Advancements in Insulin Delivery Systems

Technological advancements in insulin delivery systems are transforming diabetes care in China, making treatment more convenient and effective for patients. For instance, insulin pumps, continuous glucose monitors (CGMs), and insulin pens are transforming diabetes management in China. These innovations are enabling better glucose control and improved treatment adherence, as they provide greater accuracy, ease of use, and flexibility for patients. Insulin pens, for example, have replaced vials and syringes, offering a more discreet and precise way to administer insulin. Additionally, insulin pumps and CGM systems are becoming more widely used, particularly among patients who require intensive insulin therapy, such as those with type 1 diabetes. As these technologies become more affordable and accessible, they are expected to significantly enhance patient outcomes and drive further demand for insulin in the market. The ongoing development and adoption of these advanced insulin delivery systems are expected to remain a prominent trend in China’s insulin market in the coming years.

Strategic Investments by Global Pharmaceutical Companies

In response to the growing demand for insulin in China, global pharmaceutical companies are increasing their investments in the country’s insulin market. For instance, major players such as Sanofi, Novo Nordisk, and Eli Lilly are expanding their manufacturing capabilities and strengthening their market presence to tap into the vast potential of the Chinese healthcare market. For instance, Sanofi has made substantial investments in setting up advanced insulin production facilities in China, underscoring its commitment to increasing local production and meeting the country’s demand for diabetes treatments. Similarly, other multinational companies are also focusing on research and development in the region, tailoring insulin therapies and delivery devices to local patient needs. These investments not only help meet the growing demand for insulin but also foster innovation in the diabetes treatment space, contributing to the market’s rapid expansion. With these companies positioning themselves as key players in China’s insulin market, increased competition is expected, leading to further advancements in treatment options and enhanced patient care.

Surge in Diabetes Prevalence

The rising prevalence of diabetes in China is one of the most significant market drivers for human insulin. As the country becomes more urbanized, lifestyle changes such as poor diet, physical inactivity, and increased stress have contributed to a sharp increase in the number of diabetes cases. China currently has the largest diabetic population in the world, with estimates of over 140 million people affected by the condition. This growing population is fueling the demand for insulin as a primary treatment for diabetes, both type 1 and type 2. The government has recognized the urgency of addressing the diabetes epidemic and has made substantial investments in healthcare initiatives like the Healthy China 2030 Plan, which aims to curb the rise of chronic diseases such as diabetes. Consequently, there has been an increasing focus on improving the accessibility and availability of essential diabetes management tools, including insulin, leading to significant market expansion. The prevalence trend is expected to continue, further boosting demand for insulin products in the coming years.

Expansion of Biosimilar Insulin

One of the key trends in China’s human insulin market is the growing adoption of biosimilar insulins. Biosimilars are biologically similar to brand-name insulin products but are typically more affordable, offering an essential cost-effective option for patients, particularly in a large market like China where affordability remains a key concern. The Chinese government’s favorable regulatory policies have accelerated the approval and market entry of biosimilar insulin products. These products are now becoming increasingly popular, not only for their lower cost but also due to their ability to provide equivalent efficacy and safety to the original branded insulins. With the ongoing push for more affordable healthcare options, biosimilars are expected to play a crucial role in meeting the rising demand for insulin. This shift towards biosimilars is also expected to intensify competition among pharmaceutical companies, further driving innovation and price reductions in the insulin market. The uptake of biosimilars aligns with the government’s broader goals of improving healthcare accessibility and reducing the overall burden of diabetes.

Market Challenges Analysis

Regulatory and Pricing Pressures

One of the significant challenges facing the China human insulin market is the regulatory environment and pricing pressures. Although the Chinese government has made strides in improving healthcare access and expanding insurance coverage, the regulatory process for insulin products can be complex and time-consuming. Obtaining approval for new insulin treatments, particularly biosimilars, involves navigating a rigorous approval process that can delay market entry. Additionally, the government’s emphasis on reducing healthcare costs has led to stricter pricing controls, which can squeeze profit margins for pharmaceutical companies. The focus on affordability has encouraged the development of biosimilar insulin products, but the pricing pressures may limit the financial returns for manufacturers, especially multinational companies that rely on premium pricing strategies for branded products. This environment challenges companies to balance innovation, cost-efficiency, and compliance with regulatory requirements while ensuring competitive positioning within a highly price-sensitive market.

Competition and Market Fragmentation

Another challenge in the China human insulin market is the increasing competition and market fragmentation. For instance, with a large number of local and international players entering the market, there is significant pressure on established brands to maintain market share. Local companies often offer insulin products at lower prices, increasing competition for multinational pharmaceutical firms. Additionally, the market is fragmented with a variety of insulin delivery systems, from syringes to advanced insulin pumps, making it difficult for any single device or product type to dominate the market. Companies must navigate a competitive landscape that includes both high-quality branded insulins and affordable biosimilar options, which further complicates their ability to maintain pricing power and customer loyalty. The diverse and growing market segments—ranging from type 1 diabetes to gestational diabetes—also pose challenges in terms of targeted marketing and patient engagement, as companies must cater to varying needs and treatment preferences across different patient groups. These competitive pressures and market fragmentation require companies to continuously innovate while managing cost-effectiveness to remain successful in the rapidly evolving Chinese market.

Market Opportunities

The China human insulin market presents significant opportunities driven by the country’s growing diabetic population and evolving healthcare landscape. As urbanization continues and lifestyle-related diseases rise, the demand for diabetes management solutions, including insulin, is expanding rapidly. With over 140 million people affected by diabetes in China, the need for accessible and affordable insulin treatments is paramount. Additionally, the government’s commitment to improving healthcare infrastructure, particularly through initiatives like the Healthy China 2030 Plan, is creating a favorable environment for growth. There is also a rising demand for innovative insulin delivery devices, such as insulin pens and pumps, which offer patients more convenience and precision in managing their condition. This market trend presents a substantial opportunity for both global and local pharmaceutical companies to invest in and expand their presence in China.

Furthermore, the increasing adoption of biosimilar insulin products is another key opportunity in China’s insulin market. The government’s focus on reducing healthcare costs and improving the affordability of treatments has accelerated the approval and use of biosimilars. As patients seek more cost-effective alternatives to branded insulin, biosimilars are becoming increasingly popular due to their equivalent safety and efficacy profiles. Pharmaceutical companies that can offer high-quality biosimilars at competitive prices stand to benefit from the growing market share in this segment. Additionally, the ongoing advancements in digital health and insulin management technologies, such as continuous glucose monitoring and smart insulin pens, provide opportunities to enhance patient outcomes and improve adherence to treatment. These technological innovations, coupled with a robust regulatory framework, position China’s human insulin market as a highly promising sector for both new and existing players.

Market Segmentation Analysis:

By Device:

The China human insulin market is segmented by device into pens, syringes, and others. Among these, insulin pens dominate the market due to their convenience, ease of use, and accuracy. Insulin pens offer a more user-friendly and precise method of insulin delivery compared to traditional syringes. They are particularly popular among patients with type 1 diabetes and those who require regular insulin injections. The growth of insulin pens is further supported by technological advancements, such as pre-filled pens and smart insulin pens, which offer better dosage accuracy and ease of tracking insulin usage. Syringes, while still in use, are becoming less popular as insulin pens gain traction, but they remain essential in certain markets due to their low cost and availability. The “others” category includes insulin pumps and continuous glucose monitoring devices, which, although less widely used, are gaining traction among patients requiring intensive insulin therapy or advanced diabetes management solutions. As the adoption of advanced delivery devices continues to grow, the segment is expected to see sustained innovation and expansion.

By Indication:

The China human insulin market is also segmented by indication into type 1 diabetes, type 2 diabetes, and gestational diabetes. Type 2 diabetes holds the largest share of the market, primarily driven by lifestyle changes, such as poor diet, sedentary behavior, and urbanization, leading to a significant increase in the number of patients. Insulin is commonly used when oral medications become ineffective in controlling blood sugar levels in these patients. Type 1 diabetes, although less common than type 2, is also a significant market segment, as it requires lifelong insulin therapy. The increasing prevalence of type 1 diabetes in China is supporting steady growth in this segment. Gestational diabetes, typically diagnosed during pregnancy, represents a smaller but growing segment, driven by rising awareness and improved diagnostic capabilities. As China’s healthcare system continues to evolve, all three segments are expected to grow, with type 2 diabetes likely leading the expansion due to its higher prevalence in the population.

Segments:

Based on Device:

Pens
Syringes
Others

Based on Indication:

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Based on Insulin:

Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others

Based on Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

Based on the Geography:

Beijing
Shanghai
Guangzhou
Shenzhen

Regional Analysis

Beijing

Beijing, the capital, holds a significant share of the market, accounting for approximately 25% of the total human insulin sales in China. This is due to the city’s large population, substantial healthcare infrastructure, and the high prevalence of diabetes in the region. As the political and economic hub of China, Beijing is also a focal point for government initiatives aimed at improving diabetes management and access to insulin. The city’s advanced healthcare system, along with a growing diabetic population, positions it as a dominant player in the human insulin market, driving both demand for innovative therapies and increasing adoption of advanced insulin delivery devices.

Shanghai

Shanghai, another major city, follows closely with a market share of around 22%. Known for its rapid economic growth and development, Shanghai has become a center for pharmaceutical investments and technological advancements. The region’s increasing awareness of diabetes and the prevalence of both type 1 and type 2 diabetes have contributed to a strong demand for insulin products. With a relatively higher number of healthcare facilities, international pharmaceutical companies, and health insurance coverage in place, Shanghai sees a substantial uptake of advanced insulin therapies, including biosimilars and insulin pens. Moreover, the city’s role as an international business hub means that both local and multinational companies are investing heavily in expanding their market presence in Shanghai, further stimulating growth in this region.

Guangzhou

Guangzhou, located in the southern part of China, represents another significant market for human insulin, holding approximately 18% of the national market share. The city benefits from its position as a trade and manufacturing center, with an extensive healthcare infrastructure supporting the growing demand for diabetes care. The rising number of diabetes cases in the region, coupled with a growing aging population, has created substantial demand for insulin therapies. Guangzhou’s increasing middle-class population, coupled with rising health awareness, is expected to continue driving growth in the human insulin market. The region’s expanding healthcare access and the introduction of new technologies are expected to increase the adoption of insulin management solutions in the coming years.

Shenzhen

Shenzhen, a rapidly growing city in Guangdong province, holds around 15% of China’s human insulin market share. Known for its technological advancements and proximity to Hong Kong, Shenzhen has witnessed significant economic growth, which has positively impacted the healthcare sector. The city has seen an influx of advanced diabetes care technologies, including continuous glucose monitors and insulin pumps, making it an important hub for insulin product adoption. Shenzhen’s progressive approach to healthcare, coupled with a growing middle class and increased awareness about diabetes, provides a conducive environment for insulin product growth. As the city continues to expand its healthcare services, it is expected to see a steady increase in demand for human insulin, particularly as the diabetic population continues to rise.

Key Player Analysis

Novo Nordisk A/S
MannKind Corporation
Pfizer
Wockhardt
Biocon
Lupin
Eli Lilly and Company
Gan & Lee Pharmaceuticals
Tonghua Dongbao Pharmaceutical Co., Ltd

Competitive Analysis

The competitive landscape of China’s human insulin market is marked by the presence of both global pharmaceutical giants and strong local players. Leading international companies such as Novo Nordisk, Eli Lilly, Lupin, Biocon, MannKind Corporation, Tonghua Dongbao Pharmaceutical Co., Ltd and Pfizer dominate the market with their established brand presence and extensive distribution networks. These companies are recognized for their high-quality, innovative insulin products, including both traditional and advanced therapies, such as insulin pens, pumps, and biosimilars. The ability to offer reliable and efficient insulin treatments has positioned these global players as leaders in the sector. On the other hand, local players are gaining significant traction, particularly by focusing on cost-effective solutions that cater to China’s price-sensitive market. Many local companies are capitalizing on the growing demand for biosimilar insulin products, which are viewed as more affordable alternatives to branded insulins. These companies are also benefiting from government support, including regulatory advantages and increased access to the domestic healthcare market. Local manufacturers are making substantial investments in expanding their production capabilities and improving insulin delivery technologies to meet the rising demand for diabetes management solutions. As both local and international companies continue to innovate and compete, the Chinese human insulin market is expected to experience heightened competition, with pricing, product accessibility, and technological advancements playing critical roles in determining market success.

Recent Developments

In April 2025, Novo Nordisk announced the discontinuation of Human Mixtard, India’s largest-selling human insulin brand, as part of a global strategy to prioritize newer, patented diabetes and weight loss therapies such as Ozempic and Wegovy. While vial forms of Mixtard, Actrapid, and Insulatard will remain available, pen devices (Penfills and FlexPens) are being phased out, which is expected to disrupt patient access and preference in India.
In April 2025, Pfizer discontinued the development of danuglipron, its once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, following a case of drug-induced liver injury and after reviewing clinical and regulatory feedback. This decision halts further clinical development for both obesity and diabetes indications.
In March 2025, Biocon Biologics entered a strategic collaboration with Civica, Inc. to expand access to Insulin Aspart in the United States. Biocon will supply the drug substance, which Civica will formulate and commercialize after completing development and clinical trials.
In December 2024, Lupin acquired the Huminsulin® portfolio in India from Eli Lilly and Company. The range includes Insulin Human (Huminsulin R, NPH, 50/50, and 30/70) and is indicated for type 1 and type 2 diabetes. Lupin had previously marketed these products under a distribution agreement, and the acquisition is aimed at strengthening its diabetes portfolio.
In November 2024, MannKind’s Afrezza® (insulin human) Inhalation Powder received approval from India’s CDSCO. MannKind expects to ship product to its partner Cipla by the end of 2025.
In October 2024, Wockhardt filed for approval of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). The product, developed indigenously, will be offered in cartridges, vials, and prefilled disposable pens. This expands Wockhardt’s diabetes biosimilars portfolio and addresses a market with limited competition.

Market Concentration & Characteristics

The market concentration of China’s human insulin sector is moderately concentrated, with a few dominant global players and strong local competitors. Large multinational pharmaceutical companies hold a significant share, primarily due to their well-established insulin products and extensive distribution networks. However, local manufacturers have been gaining ground, particularly with the increasing availability of affordable biosimilar insulin. These local players are contributing to market fragmentation by offering cost-effective alternatives and competing on price sensitivity, catering to a large population with varying economic capacities. The market is also characterized by rapid technological advancements in insulin delivery devices, such as insulin pens, pumps, and continuous glucose monitoring systems, driving innovation. Additionally, the Chinese government’s policies favoring affordable diabetes care and expanding healthcare access have created a favorable environment for both multinational and local companies to thrive. As a result, while the market is dominated by a few key players, it remains dynamic and competitive, with increasing opportunities for innovation and growth.

Report Coverage

The research report offers an in-depth analysis based on Device, Indication, Insulin, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The demand for human insulin in China is expected to continue growing, driven by the increasing prevalence of diabetes.
The adoption of biosimilar insulin will rise, offering more affordable treatment options to a larger population.
Advanced insulin delivery systems, such as smart insulin pens and pumps, will see higher adoption, improving treatment precision.
The market will experience further government support through initiatives aimed at enhancing diabetes care and affordability.
Innovation in insulin formulations, including longer-acting and faster-acting insulins, will improve treatment outcomes.
Local manufacturers will continue to expand their market share by offering competitive, cost-effective insulin products.
Regional healthcare access will improve, leading to increased insulin availability in both urban and rural areas.
Increased awareness and education about diabetes management will encourage more people to seek insulin therapy.
Technological advancements in continuous glucose monitoring will drive demand for more integrated diabetes management systems.
Multinational companies will strengthen their presence through strategic investments and partnerships, further intensifying market competition.

CHAPTER NO. 1 : INTRODUCTION 19

1.1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.1.2. Key Benefits for Stakeholders 19

1.1.3. Target Audience 20

1.1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. Human Insulin Market Snapshot 21

2.1.1. China Human Insulin Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23

3.1. Russia-Ukraine and Israel-Palestine War Impacts 23

CHAPTER NO. 4 : HUMAN INSULIN MARKET – INDUSTRY ANALYSIS 24

4.1. Introduction 24

4.2. Market Drivers 25

4.2.1. Driving Factor 1 Analysis 25

4.2.2. Driving Factor 2 Analysis 26

4.3. Market Restraints 27

4.3.1. Restraining Factor Analysis 27

4.4. Market Opportunities 28

4.4.1. Market Opportunity Analysis 28

4.5. Porter’s Five Forces Analysis 29

4.6. Value Chain Analysis 30

4.7. Buying Criteria 31

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32

5.1. Import Analysis by China 32

5.1.1. China Human Insulin Market Import Volume/Revenue, By China, 2018 – 2023 32

5.2. Export Analysis by China 33

5.2.1. China Human Insulin Market Export Volume/Revenue, By China, 2018 – 2023 33

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34

6.1. Demand Analysis by China 34

6.1.1. China Human Insulin Market Demand Volume/Revenue, By China, 2018 – 2023 34

6.2. Supply Analysis by China 35

6.2.1. China Human Insulin Market Supply Volume/Revenue, By China, 2018 – 2023 35

CHAPTER NO. 7 : PRODUCTION ANALYSIS 36

7.1. Production Analysis by China 36

7.1.1. China Human Insulin Market Production Volume/Revenue, By China, 2018 – 2023 36

CHAPTER NO. 8 : PRICE ANALYSIS 37

8.1. Price Analysis by Type 37

8.1.1. China Human Insulin Market Price, By Type, 2018 – 2023 37

8.1.2. China Type Market Price, By Type, 2018 – 2023 37

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38

9.1. Key Raw Materials and Suppliers 38

9.2. Key Raw Materials Price Trend 38

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39

10.1. Manufacturing Cost Analysis 39

10.2. Manufacturing Process 39

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40

11.1. Company Market Share Analysis – 2023 40

11.1.1. China Human Insulin Market: Company Market Share, by Volume, 2023 40

11.1.2. China Human Insulin Market: Company Market Share, by Revenue, 2023 41

11.1.3. China Human Insulin Market: Top 6 Company Market Share, by Revenue, 2023 41

11.1.4. China Human Insulin Market: Top 3 Company Market Share, by Revenue, 2023 42

11.2. China Human Insulin Market Company Volume Market Share, 2023 43

11.3. China Human Insulin Market Company Revenue Market Share, 2023 44

11.4. Company Assessment Metrics, 2023 45

11.4.1. Stars 45

11.4.2. Emerging Leaders 45

11.4.3. Pervasive Players 45

11.4.4. Participants 45

11.5. Start-ups /SMEs Assessment Metrics, 2023 45

11.5.1. Progressive Companies 45

11.5.2. Responsive Companies 45

11.5.3. Dynamic Companies 45

11.5.4. Starting Blocks 45

11.6. Strategic Developments 46

11.6.1. Acquisitions & Mergers 46

New Product Launch 46

China Expansion 46

11.7. Key Players Product Matrix 47

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48

12.1. PESTEL 48

12.1.1. Political Factors 48

12.1.2. Economic Factors 48

12.1.3. Social Factors 48

12.1.4. Technological Factors 48

12.1.5. Environmental Factors 48

12.1.6. Legal Factors 48

12.2. Adjacent Market Analysis 48

CHAPTER NO. 13 : HUMAN INSULIN MARKET – BY TYPE SEGMENT ANALYSIS 49

13.1. Human Insulin Market Overview, by Type Segment 49

13.1.1. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

13.1.2. Human Insulin Market Attractiveness Analysis, By Type 51

13.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 51

13.1.4. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

13.2. Pens 53

13.3. Syringes 54

13.4. Others 55

13.5. Type 4 56

13.6. Type 5 57

CHAPTER NO. 14 : HUMAN INSULIN MARKET – BY APPLICATION SEGMENT ANALYSIS 58

14.1. Human Insulin Market Overview, by Application Segment 58

14.1.1. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

14.1.2. Human Insulin Market Attractiveness Analysis, By Application 60

14.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 60

14.1.4. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

14.2. Type 1 Diabetes 62

14.3. Type 2 Diabetes 63

14.4. Gestational Diabetes 64

14.5. Application 4 65

14.6. Application 5 66

CHAPTER NO. 15 : HUMAN INSULIN MARKET – BY END-USER SEGMENT ANALYSIS 67

15.1. Human Insulin Market Overview, by End-user Segment 67

15.1.1. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

15.1.2. Human Insulin Market Attractiveness Analysis, By End-user 69

15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 69

15.1.4. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

15.2. Rapid-acting insulin 71

15.3. Short-acting insulin 72

15.4. Intermediate-acting insulin 73

15.5. Others 74

15.6. End-user 5 75

CHAPTER NO. 16 : HUMAN INSULIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76

16.1. Human Insulin Market Overview, by Technology Segment 76

16.1.1. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

16.1.2. Human Insulin Market Attractiveness Analysis, By Technology 78

16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78

16.1.4. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

16.2. Technology 1 80

16.3. Technology 2 81

16.4. Technology 3 82

CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83

17.1. Human Insulin Market Overview, by Distribution Channel Segment 83

17.1.1. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

17.1.2. Human Insulin Market Attractiveness Analysis, By Distribution Channel 85

17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85

17.1.4. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

17.2. Hospital Pharmacies 87

17.3. Drug Stores and Retail Pharmacies 88

17.4. Online Providers 89

17.5. Distribution Channel 4 90

17.6. Distribution Channel 5 91

CHAPTER NO. 18 : HUMAN INSULIN MARKET – CHINA ANALYSIS 92

18.1. Type 92

18.1.1. China Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 92

18.2. China Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 92

18.3. Application 93

18.3.1. China Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 93

18.3.2. China Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 93

18.4. End-user 94

18.4.1. China Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 94

18.4.2. China Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 94

18.5. Technology 95

18.5.1. China Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 95

18.5.2. China Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 95

18.6. Distribution Channel 96

18.6.1. China Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96

18.6.2. China Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96

CHAPTER NO. 19 : COMPANY PROFILES 97

19.1. Novo Nordisk A/S 97

19.1.1. Company Overview 97

19.1.2. Product Portfolio 97

19.1.3. Swot Analysis 97

19.1.4. Business Strategy 98

19.1.5. Financial Overview 98

19.1.6. MannKind Corporation 99

19.1.7. Pfizer 99

19.1.8. Wockhardt 99

19.1.9. Biocon 99

19.1.10. Lupin 99

19.1.11. Tonghua Dongbao Pharmaceutical Co 99

19.1.12. Eli Lilly and Company 99

19.1.13. Gan & Lee Pharmaceuticals 99

19.1.14. Tonghua Dongbao Pharmaceutical Co., Ltd 99

19.1.15. Company 11 99

19.1.16. Company 12 99

19.1.17. Company 13 99

19.1.18. Company 14 99

CHAPTER NO. 20 : RESEARCH METHODOLOGY 100

20.1. Research Methodology 100

20.1.1. Phase I – Secondary Research 101

20.1.2. Phase II – Data Modeling 101

Company Share Analysis Model 102

Revenue Based Modeling 102

20.1.3. Phase III – Primary Research 103

20.1.4. Research Limitations 104

Assumptions 104

List of Figures

FIG NO. 1. China Human Insulin Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for China Human Insulin Market 29

FIG NO. 3. Value Chain Analysis for China Human Insulin Market 30

FIG NO. 4. China Human Insulin Market Import Volume/Revenue, By China, 2018 – 2023 32

FIG NO. 5. China Human Insulin Market Export Volume/Revenue, By China, 2018 – 2023 33

FIG NO. 6. China Human Insulin Market Demand Volume/Revenue, By China, 2018 – 2023 34

FIG NO. 7. China Human Insulin Market Supply Volume/Revenue, By China, 2018 – 2023 35

FIG NO. 8. China Human Insulin Market Production Volume/Revenue, By China, 2018 – 2023 36

FIG NO. 9. China Human Insulin Market Price, By Type, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. Human Insulin Market – Company Volume Market Share, 2023 43

FIG NO. 18. Human Insulin Market – Company Revenue Market Share, 2023 44

FIG NO. 19. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Type 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 51

FIG NO. 22. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

FIG NO. 23. China Human Insulin Market for Pens, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. China Human Insulin Market for Syringes, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. China Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. China Human Insulin Market for Type 4, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. China Human Insulin Market for Type 5, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Application 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 60

FIG NO. 31. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

FIG NO. 32. China Human Insulin Market for Type 1 Diabetes, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. China Human Insulin Market for Type 2 Diabetes, Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. China Human Insulin Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. China Human Insulin Market for Application 4, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. China Human Insulin Market for Application 5, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By End-user 69

FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69

FIG NO. 40. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

FIG NO. 41. China Human Insulin Market for Rapid-acting insulin, Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. China Human Insulin Market for Short-acting insulin, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. China Human Insulin Market for Intermediate-acting insulin, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. China Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. China Human Insulin Market for End-user 5, Revenue (USD Million) 2018 – 2032 75

FIG NO. 46. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

FIG NO. 47. Market Attractiveness Analysis, By Technology 78

FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78

FIG NO. 49. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

FIG NO. 50. China Human Insulin Market for Technology 1, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. China Human Insulin Market for Technology 2, Revenue (USD Million) 2018 – 2032 81

FIG NO. 52. China Human Insulin Market for Technology 3, Revenue (USD Million) 2018 – 2032 82

FIG NO. 53. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85

FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85

FIG NO. 56. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

FIG NO. 57. China Human Insulin Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 87

FIG NO. 58. China Human Insulin Market for Drug Stores and Retail Pharmacies, Revenue (USD Million) 2018 – 2032 88

FIG NO. 59. China Human Insulin Market for Online Providers, Revenue (USD Million) 2018 – 2032 89

FIG NO. 60. China Human Insulin Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90

FIG NO. 61. China Human Insulin Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91

FIG NO. 62. Research Methodology – Detailed View 100

FIG NO. 63. Research Methodology 101

Frequently Asked Questions

What is the current size of the China Human Insulin?

The China Human Insulin market was valued at USD 2,550.64 million in 2023 and is projected to reach USD 4,472.55 million by 2032.

What factors are driving the growth of the China Human Insulin?

Key drivers include rising diabetes prevalence, an aging population, government healthcare reforms, and growing adoption of biosimilars and insulin delivery technologies.

What are the key segments within the China Human Insulin?

The market is segmented by device (pens, syringes, others), indication (type 1, type 2, gestational diabetes), insulin type, distribution channel, and geography.

Who are the major players in the China Human Insulin?

Key players include Novo Nordisk, Eli Lilly, Pfizer, Biocon, Wockhardt, Gan & Lee Pharmaceuticals, and Tonghua Dongbao Pharmaceutical Co., Ltd.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –